The nonprofit, which is focused on advancing the cannabis industry, joins a network of industry experts from over a hundred different organizations.
In a press release (1) dated May 1, 2024, the S3 Collective, a nonprofit with the mission of “advancing the cannabis industry through collaboration, education, and standardization,” announced its acceptance into the Food and Drug Administration’s (FDA) Network of Experts (NoE) program.
“Recently, we achieved one of our milestones,” stated David Vaillencourt in a May 23, 2024, LinkedIn post regarding the announcement (2). “The FDA officially accepted our non profit into their Network of Experts program. As the 132nd organization to be accepted, I am honored to be able to provide the agency with knowledge and resources it may need on all topics of cannabinoids and psychedelics. Life is about the journey not the destination, and this is but one important step towards a future where minimum standards ensure that all products containing cannabinoids have a level of safety and quality that patients deserve.”
Vaillencourt recently participated in a panel discussion, “Federal Rescheduling: Opinions and Impacts,” at the Cannabis Science Conference in Kansas City, Missouri, which provided a range of expert opinions on the recent potential rescheduling of cannabis to a Schedule III drug.
According to the FDA (3), the NoE origins began in 2012 and the program has continued to grow as “a vetted network of partner organizations and their member scientists, clinicians and engineers who can provide the FDA rapid access to expertise when it is needed to supplement existing knowledge and expertise within the Center for Devices and Radiological Health (CDRH) and the Center for Drug Evaluation and Research (CDER).” The S3 news release added, “S3 Collective is the 132nd nonprofit organization and the first cannabis-related nonprofit to participate in this initiative.”
The FDA lists the following as requirements for an organization to be a part of the NoE (3):
“S3 Collective is uniquely positioned to contribute to the NoE program as they engage a diverse array of scientists and technical experts that champion data-driven standards for consumer protection and contribute impartial information and data to the cannabis and hemp industries,” the S3 news release stated (1). “When a need arises, S3 Collective looks forward to connecting their technical experts with the FDA to give evidence-based insights on specific topics.”
The S3 Collective was founded in 2023 by David Vaillencourt, Vice-Chair of ASTM Committee D37 on Cannabis and founder of the GMP Collective, and Alexa Wilson, Director of the Design+Build Division at Omega Equipment & Supply (4). In January of this year, the S3 Collective held a webinar, “Rescheduling Cannabis: A Scientific Imperative,” which provided an explanation of the proposed scheduling, how and why to contribute to the federal framework of cannabis regulations, and the S3 Collective's anticipated approach, with the overall goal of creating a science-based submission to the DEA’s public comment period.
References
Senate Committee has released the text of 2024 Farm Bill, with changes to hemp regulations
November 19th 2024The U.S. Senate Committee on Agriculture, Nutrition, & Forestry has introduced the Rural Prosperity and Food Security Act, which will serve as the Senate’s draft for the 2024 Farm Bill.
How cGMP Compliance Can Tackle Inconsistent Testing
November 1st 2024Inconsistent testing is a significant issue in the cannabis industry, contributing to fears about potency inflation and product safety. However, adopting cGMP compliance offers a clear solution by implementing standardized testing protocols, comprehensive batch testing, and rigorous third-party verification.